Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 417

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 417
---
 clinical testing; |

| • |     | collaborators could independently develop, or develop with third parties, products that compete directly or                                                                                                                    
 indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than us; |

| • |     | a collaborator with marketing and distribution rights to multiple products may not commit sufficient resources to                                   
 the marketing and distribution of FYARRO or any other product candidate that we may develop in the future, if approved, relative to other products; |

| • |     | we may grant exclusive rights to our collaborators that would prevent us from collaborating with others; |

| • |     | collaborators may not properly obtain, maintain, defend or enforce our intellectual property rights or may use 
 our proprietary information and intellectual property in such a way as to invite litigation or                 |

- 281 -

| other intellectual property related proceedings that could jeopardize or invalidate our proprietary information and intellectual property or expose us to potential litigation or other 
 intellectual property related proceedings;                                                                                                                                              |

| • |     | disputes may arise between the collaborators and us that result in the delay or termination of the research,                                                   
 development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources; |

| • |     | collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue 
 further development or commercialization of the applicable product candidates;                             |

| • |     | collaboration agreements may not lead to development or commercialization of FYARRO or any other product 
 candidates that we may develop in the future in the most efficient manner or at all;                     |

| • |     | collaborators may not provide us with timely and accurate information regarding development progress and                                                                                                                                                  
 activities under the collaboration or may limit our ability to share such information, which could adversely impact our ability to report progress to our investors and otherwise plan our own development of FYARRO or any other product candidates that 
 we may develop in the future;                                                                                                                                                                                                                             |

| • |     | collaborators may own or co-own intellectual property covering our                                                                                                          
 products that results from us collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and |

| • |     | a collaborator’s sales and marketing activities or other operations may not be in compliance with applicable 
 laws, resulting in civil or criminal proceedings.